Subcutaneous amivantamab is safer and more convenient for patients compared with the intravenous formulation, according to Misako Nagasaka, MD, PhD.

Mary Jo Lechowicz, MD, discussed how pre-transplant depth of response informs the choice between autologous and allogeneic HSCT in T-cell lymphoma.

Jasmine Zain, MD, described the molecular workup to determine whether a secondary malignancy after CAR T-cell therapy reflects direct insertional mutagenesis.

Misako Nagasaka, MD, PhD, explains how subcutaneous amivantamab’s shorter administration time benefits patients and infusion centers.

Misako Nagasaka, MD, PhD, discusses PALOMA-2’s 70% 3-year survival rate compared with historical MARIPOSA data for intravenous amivantamab.

Adult T-cell lymphoma and leukemia may warrant up-front allogeneic transplant, according to Mary Jo Lechowicz, MD.

The risk of infections with epcoritamab plus R2 appeared to level off after the first 4 cycles of therapy in the EPCORE FL-1 trial.

Josef Vymazal, MD, discussed how gadopiclenol’s pharmacokinetics may explain why delayed double-dose imaging outperformed delayed single-dose imaging for detecting brain metastases.